Radiopharmaceuticals have been utilized for men with advanced prostate cancer for
decades. Older agents, seldom used today, provided palliation for bone metastatic pain. In …

Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA),
making this antigen a suitable target for radioligand therapy of the disease. Here we report …

The prostate-specific membrane antigen (PSMA) inhibitor [177Lu] Lu-PSMA-617 has been
previously demonstrated to be noninferior to docetaxel in achieving a biochemical response …

Purpose Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have
been established for the treatment of metastasized castration-resistant prostate cancer …

Background Labelled with lutetium-177, the urea-based small molecules PSMA I&T and
PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients …

The development of prostate-specific membrane antigen (PSMA) ligands labeled with
radionuclides is a ground-breaking achievement in the management of prostate cancer …

Abstract Purpose:[177Lu] Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be …

97 Background: The phase 3 VISION trial (NCT03511664) evaluated the efficacy and safety
of the radioligand [177Lu] Lu-PSMA-617 (177Lu-PSMA-617) in patients with metastatic …

Introduction A new therapeutic option for metastatic castration–resistant prostate cancer
(mCRPC) of heavily pre-treated patients lies in 177 Lu-PSMA-617 radioligand therapy …

Purpose This translational study is designed to assess the safety, dosimetry and therapeutic
response to a single, low-dose of 177 Lu-EB-PSMA-617 in comparison to 177 Lu-PSMA-617 …